Trying to get my sad tired brain around some relenza figures.
Production is expected to be 190m doses, but lets be conservative and say 170m (20m freebies) x $25 per dose = 4,250m x 7% = $298m in royalties
but the other info gsk is reporting is that they expect 600 pounds, say $1,200m x 7% = $84 mill
What am I missing? Is it the lag to ramping up production or does the new delivery method produce lower revenue? Any clues anybody?
cheers
- Forums
- ASX - By Stock
- BTA
- please explain
please explain
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)